Since the revelation of poly(ADP-ribose) polymerase (PARP) inhibitors and their remarkable results in the treatment of BRCA1/2 mutant cancers, synthetic lethality (SL) in antitumor therapy has ...

Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator designed for tumors with TP53 Y220C, and observed antitumor activity across ...

Molecular model of the tumor suppressor protein p53 (beige) bound to a molecule of DNA (red and blue). P53 maintains genomic stability by controlling cell division, repairing DNA damage, and ...

Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations. In a conversation with CancerNetwork ® at the 7th International ...

Molecular dynamics simulations calculate the structure of p53m and its binding interfaces with p53-R175H and CRBN (a), and PAGE electrophoresis confirms the successful connection between p53m-DA and ...

Each year, 20 million people are diagnosed with cancer. Various organs can be affected, and cancer types sometimes differ greatly at the cellular and molecular level. In about half of all cases, ...

Rezatapopt achieved an ORR of 33% in all patients, and an ORR of 43% in patients with ovarian cancer, with 1 confirmed complete response. Interim results from the phase 2 pivotal portion of the phase ...

Schematic illustrating the effects of p53C and M237I in driving the conversion of p63C and p73C droplets into amyloid aggregates at physiologically relevant temperatures. Heparin prevents the ...

mRNA injections could reduce aggressive ovarian tumors by rescuing an often mutated gene in high-grade serous ovarian patients, according to a preclinical study. The most common form of ovarian cancer ...